Premium
Management of apnea in infants with trisomy 18
Author(s) -
Taira Ryoji,
Inoue Hirosuke,
Sawano Toru,
Fujiyoshi Junko,
Ichimiya Yuko,
Torio Michiko,
Sanefuji Masafumi,
Ochiai Masayuki,
Sakai Yasunari,
Ohga Shouichi
Publication year - 2020
Publication title -
developmental medicine and child neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.658
H-Index - 143
eISSN - 1469-8749
pISSN - 0012-1622
DOI - 10.1111/dmcn.14403
Subject(s) - trisomy , medicine , apnea , pediatrics , genetics , biology
This case series aimed to characterize the clinical features, management, and outcomes of apnea in infants with trisomy 18. Participants in this study were infants with trisomy 18 who were born alive and admitted to the neonatal intensive care unit in Kyushu University Hospital from 2000 to 2018. Retrospective analysis was performed on clinical data recorded in our department. Twenty‐seven infants with trisomy 18 were admitted to our hospital during the study period, of which 25 (nine males, 16 females) were enrolled as eligible participants in this study. Among them, 14 started presenting with apnea from median 3.5 days of age (range 0–47d). In these infants with apnea, eight received respiratory support of positive pressure ventilation (PPV). The 1‐year survival rate of infants in the PPV group was higher than that of non‐PPV‐supported infants (5 out of 8 vs 0 out of 6 infants). Five PPV‐supported infants received a diagnosis of epilepsy, which was controlled by antiepileptic drugs. Postnatal respiratory intervention provides better prognosis in infants with trisomy 18. Improved survival leads to accurate diagnosis and treatment of apneic events in association with epilepsy. What this paper adds Respiratory support is effective against apnea in infants with trisomy 18. Intervention with ventilation provides a higher chance of prolonged survival. Improved survival leads to the accurate diagnosis and treatment of epilepsy‐associated apnea.